1259018-17-1

Basic information

• Product Name: (2R₃R,4R,5S,6S)-3,4,5-tris(benzyloxy)-2-(benzyloxymethyl)-6-(3-(bromomethyl)-4-chlorophenyl)tetrahydro-2H-pyran
• Synonyms: (2R₃R,4R,5S,6S)-3,4,5-tris(benzyloxy)-2-(benzyloxymethyl)-6-(3-(bromomethyl)-4-chlorophenyl)tetrahydro-2H-pyran
• CAS NO: 1259018-17-1
• Molecular Weight: 728.123
• Mol File: 1259018-17-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (2R₃R,4R,5S,6S)-3,4,5-tris(benzyloxy)-2-(benzyloxymethyl)-6-(3-(bromomethyl)-4-chlorophenyl)tetrahydro-2H-pyran(CAS DataBase Reference)
• NIST Chemistry Reference: (2R₃R,4R,5S,6S)-3,4,5-tris(benzyloxy)-2-(benzyloxymethyl)-6-(3-(bromomethyl)-4-chlorophenyl)tetrahydro-2H-pyran(1259018-17-1)
• EPA Substance Registry System: (2R₃R,4R,5S,6S)-3,4,5-tris(benzyloxy)-2-(benzyloxymethyl)-6-(3-(bromomethyl)-4-chlorophenyl)tetrahydro-2H-pyran(1259018-17-1)

Safety Data

• Hazardous Substances Data: 1259018-17-1(Hazardous Substances Data)

Upstream product

• 1225430-37-4 (2-chloro-5-((3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenyl)methanol 
• 1259018-15-9 (2-chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenyl)methanol 

Downstream Products

• 1260073-32-2 C₄₆H₄₅ClN₂O₅S 
• 1415471-06-5 (2S,3R,4R,5S,6R)-2-(4-chloro-3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol 
• 1415471-14-5 (2S,3R,4R,5S,6R)-2-(4-chloro-3-((2,3-dihydro-1H-inden-5-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol 
• 1443119-83-2 (1S)-2,3,4,6-tetra-O-benzyl-1,5-anhydro-1-[3-(azulen-2-ylmethyl)-4-chlorophenyl]-D-glucitol 
• 1225430-39-6 2-(2-chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenyl)acetonitrile 

Relevant articles and documents

As a new polyphenylenepolymethylenepolyisocyanate deriv. SGLT2 inhibitor

A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.

Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors

Novel C-aryl glucoside SGLT2 inhibitors containing pyrimidine motif were designed and synthesized for biological evaluation. Among the compounds assayed, pyrimidine containing methylthio moiety 11g demonstrated the best in vitro inhibitory activity against SGLT2 in this series to date (IC50 = 10.7 nM).